| Category | Sensitive-Skin Care |
| Founded | 1975 |
| Headquarters | La Roche-Posay, France (L'Oréal) |
| Listing | Parent L'Oréal listed on Euronext Paris (OR) |
| Latest revenue | Parent revenue EUR 44.05bn in 2025 |
| Hero SKUs | Cicaplast Baume B5 |
Brand History
La Roche-Posay begins with a thermal spring in the small French town of the same name. In 1975 local pharmacist René Levayer turned the selenium-rich water into skincare sold to the town's dermatologists, so the brand carried a doctor-recommended DNA rather than an advertising one.
L'Oréal acquired it in 1989 and placed it in what became the Dermatological Beauty division alongside Vichy and SkinCeuticals. Its China growth came from an ingredient narrative: Cicaplast B5 for repair, Effaclar for acne, Anthelios for sun — three lines mapped to three high-frequency needs, each backed by doctors and pharmacy channels. In China it has long been one of the 'big three' pharmacy brands sharing sensitive-skin shoppers with Winona and Avène. As domestic brands close in with cheaper acquisition and faster drops, its answer is to make dermatologist endorsement harder — clinical data, hospital partnerships, post-procedure scenarios.
Hero Products
Three-Year Financials
| Year | Revenue (RMB bn) | YoY | Net profit (RMB bn) |
|---|---|---|---|
| 2023 | 411.8 | +7.6% | 61.8 |
| 2024 | 434.9 | +5.6% | 64.1 |
| 2025 | 440.5 | +1.3% | 61.3 |
Brand-level：La Roche-Posay is not reported separately but is consistently among the largest brands in L'Oréal's Dermatological Beauty division. In China it owns the pharmacy-skincare mind for sensitive and acne-prone skin and post-procedure repair, with Cicaplast B5 a perennial cross-border and e-commerce bestseller.
Source：L'Oréal annual reports; Dermatological Beauty division materials; trade press
Company Coverage
- 2026-02L'Oréal 2025 revenue EUR 44.05bn
Up 1.3%, with Dermatological Beauty remaining one of the group's fastest-growing divisions.
Source：L'Oréal FY2025 report - 2025-10Pharmacy channel crowds
Domestic sensitive-skin brands enter pharmacy and clinic channels at lower prices, widening the band.
Source：Trade media - 2025-05Post-procedure demand returns
More clinics reopen, lifting repurchase of repair products through clinical channels.
Source：Trade media
Editor's note: La Roche-Posay's China asset is that doctors are willing to recommend it, not the thermal water. That gives it a lower cost of trust than advertising-led brands. The risk: once every brand tells an ingredient and clinical story, dermatologist endorsement becomes scarce — and brands do not control how that scarcity is allocated.